Etavopivat A 200 mg
NN7535-7822
Phase 3 small_molecule active
Quick answer
Etavopivat A 200 mg for Sickle Cell Disease and Thalassaemia is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Sickle Cell Disease and Thalassaemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active